Immune response in progressive multifocal leukoencephalopathy: An overview

Journal of NeuroVirology

Volumn 7, Issue 4, 2001, Pages 311-317

  Weber, T ^a   Weber, F ^a   Petry, H ^a   Luke W ^a  

^a Marienkrankenhaus Hamburg   (Germany)

Author keywords

Cellular immune response; Cerebrospinal fluid; Humoral immune response; Intrathecal immune response; PML

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; RECOMBINANT PROTEIN; VIRUS PROTEIN;

ANTIBODY DETECTION; ARTICLE; CELL PROLIFERATION; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DIAGNOSTIC TEST; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; LYMPHOCYTE FUNCTION; MONONUCLEAR CELL; PERSISTENT INFECTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; SERUM; TH1 CELL; VIRUS LOAD;

ANTIBODY FORMATION; HUMANS; IMMUNITY, CELLULAR; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL;

EID: 0034820498     PISSN: 13550284     EISSN: None     Source Type: Journal    
DOI: 10.1080/13550280152537166     Document Type: Article

References (53)

1. Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy
2. Progressive multifocal leukoencephalopathy. A hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease
3. Remission of progressive multifocal leucoencephalopathy after antiretroviral therapy
4. Regression of progressive multifocal encephalopathy with highly active antiretroviral therapy
5. Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. A review of the literature with a report of sixteen cases
6. Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy
7. Progressive multifocal leukoencephalopathy in a renal transplant patient diagnosed by JCV-specific DNA amplification and an intrathecal humoral immune response to recombinant virus protein 1
8. Papovavirus antigens in paraffin sections of PML brains
9. Clinical and virological monitoring during treatment with intrathecal cytarabine in patients with AIDS-associated progressive multifocal leukoencephalopathy
10. Remission of progressive multifocal leucoencephalopathy after antiretroviral therapy
11. Progressive multifocal leukoencephalopathy: Improved survival of human immunodeficiency virus-infected patients in the protease inhibitor era
12. Quantification of JC virus DNA in the cerebrospinal fluid of patients with human immunodeficiency virus-associated progressive multifocal leukoencephalopathy-a longitudinal study
13. 2.5 year remission of AIDS-associated progressive multifocal leukoencephalopathy with combined antiretroviral therapy
14. Progressive multifocal leukoencephalopathy (PML). I. Investigation of the immunologic status of a patient with lymphosarcoma and PML
15. Efficient production of JC virus in SVG cells and the use of purified viral antigens for analysis of specific humoral and cellular immune response
16. Prolonged survival without neurological improvement in patients with AIDS-related progressive multifocal leukoencephalopathy on potent combined antiretroviral therapy
17. Highly active antiretroviral therapy and progressive multifocal leukoencephalopathy: Effects on cerebrospinal fluid markers of JC virus replication and immune response
18. Molecular cloning and expression of major structural protein VP1 of the human polyomavirus JC virus: Formation of virus-like particles useful for immunological and therapeutic studies
19. Progressive multifocal leukoencephalopathy: Simultaneous detection of JCV DNA and anti-JCV antibodies in the cerebrospinal fluid
20. Remission of progressive multifocal leukoencephalopathy following highly active antiretroviral therapy in a patient with HIV infection
21. Progressive multifocal leukoencephalopathy complicating Wiskott-Aldrich syndrome. Report of a case and review of the literature of progressive multifocal leukoencephalopathy with other inherited immunodeficiency states
22. "Spontaneous" progressive multifocal leukoencephalopathy. Immunologic aspects
23. The JC virus antibody response in serum and cerebrospinal fluid in progressive multifocal leukoencephalopathy
24. JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy
25. JC virus-specific cytotoxic T lymphocytes in patients with AIDS-associated progressive multifocal leukoencephalopathy
26. Progressive multifocal leukoencephalopathy (PML) in the acquired immunodeficiency syndrome (AIDS). A neuropathological autopsy study of 21 cases
27. Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain
28. Progressive multifocal leukoencephalopathy: Clinical and laboratory observations on a viral induced demyelinating disease in the immunodeficient patient
29. Treatment of AIDS-associated progressive multifocal leukoencephalopathy with highly active antiretroviral therapy
30. Reduced concentrations of HIV-RNA and TNF-alpha coexist in CSF of AIDS patients with progressive multifocal leukoencephalopathy
31. Cytomegalovirus-induced T-cell proliferation and the development of progressive multifocal leukoencephalopathy following bone marrow transplantation
32. Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy
33. New human papovaviruses
34. Virologic and serologic studies of progressive multifocal leukoencephalopathy
35. JC Papovavirus in progressive multifocal leukoencephalopathy
36. Progressive multifocal leukoencephalopathy: Immunofluorescent demonstration of simian virus 40 antigen in CSF cells and response to cytarabine therapy
37. Remission of progressive multifocal leukoencephalopathy following splenectomy and antiretroviral therapy in a patient with HIV infection
38. Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system
39. Quantification of virus-specific antibodies in cerebrospinal fluid and serum: Sensitive and specific detection of antibody synthesis in brain
40. Progressive multifocal leukoencephalopathy
41. Absence of immune deficiencies in a case of progressive multifocal leukoencephalopathy
42. The intrathecal synthesis of virus-specific oligoclonal IgG in multiple sclerosis
43. Detection of CSF-specific oligoclonal antibodies to recombinant JC virus VP1 in patients with progressive multifocal leukoencephalopathy
44. Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy
45. Highly active antiretroviral therapy does not improve survival of patients with high JC virus load in the cerebrospinal fluid at progressive multifocal leukoencephalopathy diagnosis
46. Progressive multifocal leukoencephalopathy regression with highly active antiretroviral therapy
47. Progressive multifocal leukoencephalopathy
48. The use of recombinant antigens in ELISA procedures for the quantification of intrathecally produced HIV-1-specific antibodies
49. Clinical implications of nucleic acid amplification methods for the diagnosis of viral infections of the nervous system
50. Humoral and cellular immune response in progressive multifocal leukoencephalopathy
51. Analysis of the systemic and intrathecal humoral immune response in progressive multifocal leukoencephalopathy
52. Progressive multifocal leukoencephalopathy (PML): In vitro cell-mediated immune response to mitogens and JC virus
53. Relation of JC virus DNA in the cerebrospinal fluid to survival in acquired immunodeficiency syndrome patients with biopsy-proven progressive multifocal leukoencephalopathy